Athos Entered into a Proteomics Research Collaboration with Caltech to Advance AI Platform for Inflammatory Bowel Disease
Shots:
- The companies collaborated to advance the internal omics AI platform using proteomics analysis & also advances the Athos platform & spectrometry-based proteomics for IBD
- Athos will use specialized facilities and equipment at Caltech to perform molecular analysis and spectrometry-based proteomics using cultured cells and biopsies from archived and de-identified IBD patient samples
- The proteomics analysis results are interrelated with clinical info. Incl. IBD subtypes, patient age, sex, disease location, prior treatments, and status. Athos can able to describe disease networks, identify patient subtypes, discover novel biomarkers & identify druggable therapeutic targets by combining proteome study with existing genomic data
Ref: PRNewswire | Image: Athos
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
